标题/作者	年份
Proteogenomic landscape of breast cancer tumorigenesis and targeted therapy K Krug, EJ Jaehnig, S Satpathy, L Blumenberg, A Karpova, M Anurag, ... Cell 183 (5), 1436-1456. e31	2020
Regulating tumor suppressor genes: post-translational modifications L Chen, S Liu, Y Tao Signal transduction and targeted therapy 5 (1), 90	2020
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015–2019) C Sánchez-Martínez, MJ Lallena, SG Sanfeliciano, A de Dios Bioorganic & medicinal chemistry letters 29 (20), 126637	2019
Efficacy of PI3K inhibitors in advanced breast cancer B Verret, J Cortes, T Bachelot, F Andre, M Arnedos Annals of Oncology 30, x12-x20	2019
Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences CL Braal, EM Jongbloed, SM Wilting, RHJ Mathijssen, SLW Koolen, ... Drugs 81, 317-331	2021
Therapy-induced senescence: opportunities to improve anticancer therapy PG Prasanna, DE Citrin, J Hildesheim, MM Ahmed, S Venkatachalam, ... JNCI: Journal of the National Cancer Institute 113 (10), 1285-1298	2021
PROTACs suppression of CDK4/6, crucial kinases for cell cycle regulation in cancer B Zhao, K Burgess Chemical communications 55 (18), 2704-2707	2019
Systematic exploration of different E3 ubiquitin ligases: an approach towards potent and selective CDK6 degraders C Steinebach, YLD Ng, I Sosič, CS Lee, S Chen, S Lindner, LP Vu, ... Chemical science 11 (13), 3474-3486	2020
Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib M Poratti, G Marzaro European Journal of Medicinal Chemistry 172, 143-153	2019
Cell cycle on the crossroad of tumorigenesis and cancer therapy J Liu, Y Peng, W Wei Trends in cell biology 32 (1), 30-44	2022
DMDRMR-mediated regulation of m6A-modified CDK4 by m6A reader IGF2BP3 drives ccRCC progression Y Gu, S Niu, Y Wang, L Duan, Y Pan, Z Tong, X Zhang, Z Yang, B Peng, ... Cancer research 81 (4), 923-934	2021
Cyclin-dependent kinases 4/6 inhibitors in breast cancer: current status, resistance, and combination strategies Y Niu, J Xu, T Sun Journal of Cancer 10 (22), 5504	2019
CDK4/6 regulate lysosome biogenesis through TFEB/TFE3 Q Yin, Y Jian, M Xu, X Huang, N Wang, Z Liu, Q Li, J Li, H Zhou, L Xu, ... Journal of Cell Biology 219 (8), e201911036	2020
Targeting CDK4 and CDK6 in cancer S Goel, JS Bergholz, JJ Zhao Nature Reviews Cancer 22 (6), 356-372	2022
Targeting cell cycle in breast cancer: CDK4/6 inhibitors M Piezzo, S Cocco, R Caputo, D Cianniello, GD Gioia, VD Lauro, G Fusco, ... International Journal of Molecular Sciences 21 (18), 6479	2020
NRAS mutant melanoma: Towards better therapies T Randic, I Kozar, C Margue, J Utikal, S Kreis Cancer treatment reviews 99, 102238	2021
Proteolysis-targeting chimeras (PROTACs) in cancer therapy X Li, W Pu, Q Zheng, M Ai, S Chen, Y Peng Molecular Cancer 21 (1), 1-30	2022
Context is everything: extrinsic signalling and gain-of-function p53 mutants I Amelio, G Melino Cell Death Discovery 6 (1), 16	2020
Overcoming the senescence‐associated secretory phenotype (SASP): a complex mechanism of resistance in the treatment of cancer CR Chambers, S Ritchie, BA Pereira, P Timpson Molecular oncology 15 (12), 3242-3255	2021
Use of ratiometrically designed nanocarrier targeting CDK4/6 and autophagy pathways for effective pancreatic cancer treatment Y Ji, X Liu, J Li, X Xie, M Huang, J Jiang, YP Liao, T Donahue, H Meng Nature Communications 11 (1), 4249	2020

1 - 20

计算机程序会自动估算并确定日期和引用次数。